PL4161505T3 - Kompozycja do normalizacji stłuszczenia wątroby i sposób jej wytwarzania - Google Patents

Kompozycja do normalizacji stłuszczenia wątroby i sposób jej wytwarzania

Info

Publication number
PL4161505T3
PL4161505T3 PL21818356.4T PL21818356T PL4161505T3 PL 4161505 T3 PL4161505 T3 PL 4161505T3 PL 21818356 T PL21818356 T PL 21818356T PL 4161505 T3 PL4161505 T3 PL 4161505T3
Authority
PL
Poland
Prior art keywords
normalisation
producing
composition
same
fatty liver
Prior art date
Application number
PL21818356.4T
Other languages
English (en)
Inventor
David Sue San Ho
Sarah Lee-Mun HO
Original Assignee
Hovid Berhad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovid Berhad filed Critical Hovid Berhad
Publication of PL4161505T3 publication Critical patent/PL4161505T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Meat, Egg Or Seafood Products (AREA)
PL21818356.4T 2020-06-04 2021-06-03 Kompozycja do normalizacji stłuszczenia wątroby i sposób jej wytwarzania PL4161505T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2020002852A MY210343A (en) 2020-06-04 2020-06-04 Composition for normalisation of fatty liver and method for producing the same
PCT/MY2021/050043 WO2021246861A1 (en) 2020-06-04 2021-06-03 Composition for normalisation of fatty liver and method for producing the same

Publications (1)

Publication Number Publication Date
PL4161505T3 true PL4161505T3 (pl) 2026-01-19

Family

ID=78830522

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21818356.4T PL4161505T3 (pl) 2020-06-04 2021-06-03 Kompozycja do normalizacji stłuszczenia wątroby i sposób jej wytwarzania

Country Status (7)

Country Link
EP (1) EP4161505B8 (pl)
AU (1) AU2021283774A1 (pl)
ES (1) ES3054078T3 (pl)
MY (1) MY210343A (pl)
PL (1) PL4161505T3 (pl)
WO (1) WO2021246861A1 (pl)
ZA (1) ZA202213079B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY203355A (en) * 2021-12-27 2024-06-25 Sd Guthrie Intellectual Property Sdn Bhd Self-emulsifying composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
WO2002026324A2 (en) * 2000-09-27 2002-04-04 Sonus Pharmaceuticals, Inc. Tocol-based compositions containing amiodarone
TWI759260B (zh) * 2015-01-02 2022-04-01 美商梅拉洛伊卡公司 多元補充品組成物
CN105983013A (zh) * 2015-03-23 2016-10-05 天士力制药集团股份有限公司 一种含有水飞蓟宾、葛根提取物的药物组合物
MY192213A (en) * 2016-05-23 2022-08-08 Attest Res Sdn Bhd A composition for preventing or mitigating dementia
CN107320468A (zh) * 2017-07-05 2017-11-07 刘彦博 复合磷脂脂质体口服液及其制备方法和应用
JP7379348B2 (ja) * 2017-10-11 2023-11-14 バスト バイオテクノロジー 線維症の治療のための組成物および方法

Also Published As

Publication number Publication date
AU2021283774A1 (en) 2023-01-19
EP4161505B1 (en) 2025-09-03
MY210343A (en) 2025-09-12
ZA202213079B (en) 2024-09-25
EP4161505A1 (en) 2023-04-12
EP4161505B8 (en) 2025-11-26
ES3054078T3 (en) 2026-01-29
EP4161505C0 (en) 2025-09-03
WO2021246861A1 (en) 2021-12-09
EP4161505A4 (en) 2024-06-12
TW202146003A (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
EP3635095A4 (en) LIVER ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
IL304214A (en) Preparations and methods for the treatment of metabolic and liver disorders
PL4036143T3 (pl) Dwuczęściowa epoksydowa kompozycja elastomerowa zawierająca ester fosforanowy i sposób jej stosowania
GB202011871D0 (en) Composition and method
IL309043A (en) Crystalline Abdenase compositions and methods for their preparation and use
PL4161505T3 (pl) Kompozycja do normalizacji stłuszczenia wątroby i sposób jej wytwarzania
AU2021347431B2 (en) Method of treating fatty liver disease
GB2593010B (en) Composition and Method
GB202100998D0 (en) Composition and method
GB202100997D0 (en) Composition and method
LT4027976T (lt) Rifabutino kompozicijos ir gamybos būdas
GB202013271D0 (en) Composition and method
GB202010449D0 (en) Method and composition
EP3616705A4 (en) COMPOSITION WITH AMOMUM VILLOSUM TO IMPROVE THE PREVENTION AND TREATMENT OF FATTY LIVER
SG11202012283XA (en) Additive composition and method of preparing the same
GB202109827D0 (en) Method and composition
GB202102310D0 (en) Composition and method
GB202016644D0 (en) Composition and method
IL316459A (en) Cannabinoid compositions and methods for their production
GB202003327D0 (en) Beverage composition and method of forming the same
GB202001454D0 (en) Method and composition of increasing antioxidant
HK40072394A (en) Shaped organoid compositions and methods of making same
HK40028143A (en) Liver organoid compositions and methods of making and using same
GB202113086D0 (en) Composition and method
GB202113085D0 (en) Composition and method